Tumours display considerable variation in the patterning and properties of angiogenic blood
vessels, as well as in their responses to anti-angiogenic therapy. Angiogenic programming …

Tumors require a blood supply for growth and hematogenous dissemination. Much attention
has been focused on the role of angiogenesis—the recruitment of new vessels into a tumor …

Inadequate presentation of tumor antigens by host professional antigen–presenting cells
(APCs), including dendritic cells (DCs), is one potential mechanism for the escape of tumors …

A substantial number of clinical trials using antiangiogenic therapies are ongoing worldwide.
How to achieve the maximum benefit from these therapies and how to monitor patient …

We performed a meta-analysis of all published studies relating intratumoural microvessel
density (MVD)(45 studies) or vascular endothelial growth factor (VEGF) expression (27 …

BACKGROUND Clinical data clearly indicate a correlation between tumor
neovascularization, aggressiveness of tumor growth, and metastatic spread. One of the key …

BACKGROUND To identify the role of survivin, a novel inhibitor of apoptosis (IAP) in
colorectal tumorigenesis, the authors investigated tissue expression of survivin in human …

Elevated tumor interstitial fluid pressure (IFP) is partly responsible for the poor penetration
and distribution of therapeutic agents in solid tumors. The etiology of tumor interstitial …

Purpose Bevacizumab is a monoclonal antibody to vascular endothelial growth factor-A
(VEGF). In the pivotal trial in metastatic colorectal cancer (mCRC), addition of bevacizumab …

The angiogenic factor vascular endothelial growth factor-D (VEGF-D) isa ligand for VEGF
receptor-3 (VEGFR-3/Flt-4) and receptor-2 (VEGFR-2/KDR) and is implicated in the …